PepGen Aktie
WKN DE: A3DKVW / ISIN: US7133171055
13.03.2024 13:05:28
|
PepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51
(RTTNews) - Wednesday, PepGen Inc. (PEPG) announced that PGN-EDO51, a potential therapeutic for Duchenne muscular dystrophy or DMD patients, has received orphan drug and rare pediatric disease designations from the FDA.
The company said that PGN-EDO51 is anticipated to be beneficial for patients with mutations suitable for the exon 51 skipping approach.
PepGen is presently assessing PGN-EDO51 in the CONNECT 1 Phase 2 trial and intends to commence patient enrollment in the CONNECT 2 Phase 2 trial later this year.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PepGen Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu PepGen Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
PepGen Inc Registered Shs | 5,88 | 121,05% |
|